NEW DELHI – Artificial intelligence (AI) is increasingly gaining a foothold in India's health care landscape, with investors pouring money into the new technology, companies developing products and regulators looking to come up with much-needed rules.

BEIJING – With home-grown artificial intelligence (AI) medical devices under priority review, mainland China is quickly putting together a regulatory framework to more rapidly tap into the power of AI to develop devices and drugs.

HONG KONG – With an aging population and a shortage of doctors, Japan is now working to develop artificial intelligence (AI)-based medicine faster than any other country in Asia.

HONG KONG – South Korea is actively working to expand its artificial intelligence (AI) capabilities in health care, but outdated regulations and concerns over privacy and profit sharing are proving to be significant stumbling blocks.

Cmab Biopharma Inc. and Suzhou Kintor Pharmaceuticals Inc., both of Suzhou, China, are collaborating on the development and manufacturing of Kintor's ALK-1 MAb, a monoclonal antibody targeting activin receptor-like kinase-1 that was licensed from New York-based Pfizer Inc.

HONG KONG – South Korean biotech venture Crystal Genomics Inc., based in Seongnam City, Gyeonggi-do, said it signed a memorandum of understanding for a strategic partnership with Bellevue Asset Management AG, a global asset manager headquartered in Küsnacht, Switzerland.

RIYADH, Saudi Arabia – Saudi Arabia, a country best known as one of the world's largest oil producers, is looking to develop a stronger domestic biotech and pharmaceutical industry, partly to diversify its economy and partly to address its domestic health care needs.

BEIJING – Look out, Hong Kong Stock Exchange (HKEX). Chinese pre-profit biotech startups are now starting to apply for listing on Shanghai's sci-tech innovation board known as the STAR, with the latest application filed by HIV drugmaker Frontier Biotechnologies Inc., of Nanjing.